Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Clorox (CLX) downgraded to Hold from Buy at Argus with analyst John Staszak saying that while the company is benefiting from low-cost operations and strong market share, margin pressure and private-label competition pose obstacles to its growth. 2. Cosan (CZZ) downgraded to Neutral from Buy at UBS. 3. Inphi (IPHI) downgraded to Underperform from Neutral at BofA/Merrill with analyst Vivek Arya citing "materially worse" first quarter guidance led by persistent inventory issues in the coherent transimpedance amplifier/driver business in China. 4. Enanta (ENTA) downgraded to Neutral from Overweight at JPMorgan with analyst Jessica Fye saying she believes improved hepatitis C virus royalties and a lower U.S. tax rate are now reflected in the shares. 5. Allison Transmission (ALSN) downgraded to Neutral from Buy at BofA/Merrill with analyst Ross Gilardi saying he expects a strong fourth quarter driven by robust growth in its high margin spare parts business and a recovery in its Off-Highway segment but sees some risks to operating leverage next year due to business mix and higher R&D. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

"We are reaffirming our full year 2024 guidance provided to the market on February 13. Allison expects 2024 Net Sales in the range of $3,050 to $3,150 million, Net Income in the range of $635 to $685 million, Adjusted EBITDA in the range of $1,070 to $1,130 million, Net Cash Provided by Operating Activities in the range of $700 to $760 million, Capital Expenditures in the range of $125 to $135 million, and Adjusted Free Cash Flow in the range of $575 to $625 million."